128 related articles for article (PubMed ID: 12396602)
1. HIV-1 Tat-based vaccines: from basic science to clinical trials.
Fanales-Belasio E; Cafaro A; Cara A; Negri DR; Fiorelli V; Butto S; Moretti S; Maggiorella MT; Baroncelli S; Michelini Z; Tripiciano A; Sernicola L; Scoglio A; Borsetti A; Ridolfi B; Bona R; Ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Vardas E; Magnani M; Laguardia E; Caputo A; Titti F; Ensoli B
DNA Cell Biol; 2002 Sep; 21(9):599-610. PubMed ID: 12396602
[TBL] [Abstract][Full Text] [Related]
2. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.
Maggiorella MT; Baroncelli S; Michelini Z; Fanales-Belasio E; Moretti S; Sernicola L; Cara A; Negri DR; Buttò S; Fiorelli V; Tripiciano A; Scoglio A; Caputo A; Borsetti A; Ridolfi B; Bona R; ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Ciccozzi M; Heeney J; Titti F; Cafaro A; Ensoli B
Vaccine; 2004 Sep; 22(25-26):3258-69. PubMed ID: 15308348
[TBL] [Abstract][Full Text] [Related]
3. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.
Cafaro A; Caputo A; Fracasso C; Maggiorella MT; Goletti D; Baroncelli S; Pace M; Sernicola L; Koanga-Mogtomo ML; Betti M; Borsetti A; Belli R; Akerblom L; Corrias F; Buttò S; Heeney J; Verani P; Titti F; Ensoli B
Nat Med; 1999 Jun; 5(6):643-50. PubMed ID: 10371502
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses.
Richardson MW; Mirchandani J; Silvera P; Régulier EG; Capini C; Bojczuk PM; Hu J; Gracely EJ; Boyer JD; Khalili K; Zagury JF; Lewis MG; Rappaport J
DNA Cell Biol; 2002 Sep; 21(9):637-51. PubMed ID: 12396606
[TBL] [Abstract][Full Text] [Related]
5. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.
Ensoli B; Cafaro A
J Biol Regul Homeost Agents; 2000; 14(1):22-6. PubMed ID: 10763887
[TBL] [Abstract][Full Text] [Related]
6. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
7. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.
Cafaro A; Caputo A; Maggiorella MT; Baroncelli S; Fracasso C; Pace M; Borsetti A; Sernicola L; Negri DR; Ten Haaft P; Betti M; Michelini Z; Macchia I; Fanales-Belasio E; Belli R; Corrias F; Buttò S; Verani P; Titti F; Ensoli B
J Med Primatol; 2000 Aug; 29(3-4):193-208. PubMed ID: 11085582
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.
Fanales-Belasio E; Moretti S; Fiorelli V; Tripiciano A; Pavone Cossut MR; Scoglio A; Collacchi B; Nappi F; Macchia I; Bellino S; Francavilla V; Caputo A; Barillari G; Magnani M; Laguardia ME; Cafaro A; Titti F; Monini P; Ensoli F; Ensoli B
J Immunol; 2009 Mar; 182(5):2888-97. PubMed ID: 19234184
[TBL] [Abstract][Full Text] [Related]
9. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
10. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).
Cafaro A; Titti F; Fracasso C; Maggiorella MT; Baroncelli S; Caputo A; Goletti D; Borsetti A; Pace M; Fanales-Belasio E; Ridolfi B; Negri DR; Sernicola L; Belli R; Corrias F; Macchia I; Leone P; Michelini Z; ten Haaft P; Buttò S; Verani P; Ensoli B
Vaccine; 2001 Apr; 19(20-22):2862-77. PubMed ID: 11282197
[TBL] [Abstract][Full Text] [Related]
12. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
Verrier B; Le Grand R; Ataman-Onal Y; Terrat C; Guillon C; Durand PY; Hurtrel B; Aubertin AM; Sutter G; Erfle V; Girard M
DNA Cell Biol; 2002 Sep; 21(9):653-8. PubMed ID: 12396607
[TBL] [Abstract][Full Text] [Related]
13. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination.
Castaldello A; Brocca-Cofano E; Voltan R; Triulzi C; Altavilla G; Laus M; Sparnacci K; Ballestri M; Tondelli L; Fortini C; Gavioli R; Ensoli B; Caputo A
Vaccine; 2006 Jul; 24(29-30):5655-69. PubMed ID: 16781023
[TBL] [Abstract][Full Text] [Related]
14. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.
Buttò S; Fiorelli V; Tripiciano A; Ruiz-Alvarez MJ; Scoglio A; Ensoli F; Ciccozzi M; Collacchi B; Sabbatucci M; Cafaro A; Guzmán CA; Borsetti A; Caputo A; Vardas E; Colvin M; Lukwiya M; Rezza G; Ensoli B;
J Infect Dis; 2003 Oct; 188(8):1171-80. PubMed ID: 14551888
[TBL] [Abstract][Full Text] [Related]
15. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env.
Ensoli B; Cafaro A; Caputo A; Fiorelli V; Ensoli F; Gavioli R; Ferrantelli F; Cara A; Titti F; Magnani M
Microbes Infect; 2005 Nov; 7(14):1392-9. PubMed ID: 16243561
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the development of HIV-1 Tat-based vaccines.
Caputo A; Gavioli R; Ensoli B
Curr HIV Res; 2004 Oct; 2(4):357-76. PubMed ID: 15544457
[TBL] [Abstract][Full Text] [Related]
17. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
18. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses.
Fanales-Belasio E; Moretti S; Nappi F; Barillari G; Micheletti F; Cafaro A; Ensoli B
J Immunol; 2002 Jan; 168(1):197-206. PubMed ID: 11751963
[TBL] [Abstract][Full Text] [Related]
19. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates.
Mascarell L; Bauche C; Fayolle C; Diop OM; Dupuy M; Nougarede N; Perraut R; Ladant D; Leclerc C
Vaccine; 2006 Apr; 24(17):3490-9. PubMed ID: 16524647
[TBL] [Abstract][Full Text] [Related]
20. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
Turbant S; Martinon F; Moine G; Le Grand R; Léonetti M
Vaccine; 2009 Aug; 27(39):5349-56. PubMed ID: 19607953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]